Literature DB >> 3360052

Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine.

B Olsson1, M Johansson, J Gabrielsson, P Bolme.   

Abstract

The pharmacokinetics and bioavailability of N-acetylcysteine (NAC) have been determined after its intravenous and oral administration to 6 healthy volunteers. According to a randomized cross-over design each subject received NAC 200 mg i.v. and 400 mg p.o., and blood samples were collected for 30 h. Reduced NAC had a volume of distribution (VSS) of 0.59 l.kg-1 and a plasma clearance of 0.84 l.h-1.kg-1. The terminal half-life after intravenous administration was 1.95 h. The oral bioavailability was 4.0%. Based on total NAC concentration, its volume of distribution (VSS) was 0.47 l.kg-1 and its plasma clearance was 0.11 l.h-1.kg-1. The terminal half-life was 5.58 h after intravenous administration and 6.25 h after oral administration. Oral bioavailability of total NAC was 9.1%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3360052     DOI: 10.1007/bf01061422

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Effect of oral N-acetylcysteine on mucus clearance.

Authors:  A B Millar; D Pavia; J E Agnew; M T Lopez-Vidriero; D Lauque; S W Clarke
Journal:  Br J Dis Chest       Date:  1985-07

2.  N-acetylcysteine for paracetamol overdose.

Authors:  L G Tee; A R Boobis; D S Davies
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Determination of non-protein-bound N-acetylcysteine in plasma by high-performance liquid chromatography.

Authors:  B Kågedal; M Källberg; J Mårtensson
Journal:  J Chromatogr       Date:  1984-11-09

4.  Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

5.  N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites.

Authors:  L R Morgan; M R Holdiness; L E Gillen
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

6.  Long-term oral acetylcysteine in chronic bronchitis. a double-blind controlled study.

Authors: 
Journal:  Eur J Respir Dis Suppl       Date:  1980

7.  Determination of N-acetylcysteine, intact and oxidized, in plasma by column liquid chromatography and post-column derivatization.

Authors:  M Johansson; D Westerlund
Journal:  J Chromatogr       Date:  1987-01-09

8.  N-acetylcysteine (NAC): a significant chemoprotective adjunct. Proceedings of a symposium, September 8 and 10, 1982.

Authors: 
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

9.  Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.

Authors:  G Boman; U Bäcker; S Larsson; B Melander; L Wåhlander
Journal:  Eur J Respir Dis       Date:  1983-08

10.  Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine.

Authors:  L F Prescott; J Park; A Ballantyne; P Adriaenssens; A T Proudfoot
Journal:  Lancet       Date:  1977-08-27       Impact factor: 79.321

View more
  75 in total

Review 1.  Respiratory muscle function and free radicals: from cell to COPD.

Authors:  L M Heunks; P N Dekhuijzen
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

2.  Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease.

Authors:  Thomas D Nolin; Rosemary Ouseph; Jonathan Himmelfarb; M Elizabeth McMenamin; Richard A Ward
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

3.  Investigation of the therapeutic potential of N-acetyl cysteine and the tools used to define nigrostriatal degeneration in vivo.

Authors:  Negin Nouraei; Lauren Zarger; Justin N Weilnau; Jimin Han; Daniel M Mason; Rehana K Leak
Journal:  Toxicol Appl Pharmacol       Date:  2016-02-12       Impact factor: 4.219

4.  Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise.

Authors:  Malcolm Brown; Andrew Bjorksten; Ivan Medved; Michael McKenna
Journal:  Eur J Clin Pharmacol       Date:  2004-11-20       Impact factor: 2.953

Review 5.  Contrast-induced acute kidney injury and diabetic nephropathy.

Authors:  Andrew D Calvin; Sanjay Misra; Axel Pflueger
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

Review 6.  Evidence for the changing regimens of acetylcysteine.

Authors:  Angela L Chiew; Geoffrey K Isbister; Stephen B Duffull; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2015-11-23       Impact factor: 4.335

7.  Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects.

Authors:  T T Knudsen; S Thorsen; S A Jensen; K Dalhoff; L E Schmidt; U Becker; F Bendtsen
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

8.  N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients.

Authors:  Tariq Rehman; Jason Fought; Richard Solomon
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

9.  High dose intracoronary N-acetylcysteine in a porcine model of ST-elevation myocardial infarction.

Authors:  Markus Meyer; Stephen P Bell; Zengyi Chen; Iwan Nyotowidjojo; Richard R Lachapelle; Timothy F Christian; Pamela C Gibson; Friederike F Keating; Harold L Dauerman; Martin M LeWinter
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

10.  N-acetylcysteine decreased nicotine self-administration and cue-induced reinstatement of nicotine seeking in rats: comparison with the effects of N-acetylcysteine on food responding and food seeking.

Authors:  Ana M Ramirez-Niño; Manoranjan S D'Souza; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.